How Lean Mass Preservation Changes with Age
Lean mass preservation declines with age due to anabolic resistance and hormonal shifts. This article reviews the mechanisms and investigational compounds studied in laboratory and clinical research, including GLP-1 rece
Research Studies
Age-related changes in lean mass and the role of GLP-1 receptor agonists
Obesity affects over 2 billion adults globally, with projections indicating that nearly two-thirds of adults will be affected by 2050 [1]. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed obesity treatment, achieving weight loss previously considered attainable only with bariatric surgery. However, GLP-1-based therapies have revealed important limitations, including weight loss plateaus, substantial inter-individual variability, and weight regain upon discontinuation, underscoring the need for next-generation approaches [1]. In the context of lean mass preservation, these therapies have been associated with loss of lean mass alongside fat mass, raising questions about the quality of weight loss, particularly in older adults who may already be at risk for sarcopenia.
Trevogrumab and garetosmab with semaglutide for lean mass preservation
A clinical study is investigating trevogrumab and garetosmab, experimental drugs, in combination with semaglutide (Wegovy®) in adult patients with obesity for weight loss, fat loss, and lean mass preservation [2]. The study is divided into three parts: Part A focuses on healthy participants to assess safety and tolerability; Parts B and C focus on participants with obesity to evaluate safety and efficacy when combined with semaglutide [2]. This research aims to determine whether adding these agents can mitigate the loss of lean mass often observed with GLP-1 receptor agonist therapy alone.
Myostatin inhibition and muscle mass regulation in aging models
Myostatin, a member of the TGF-β superfamily, is a negative regulator of muscle growth. Inhibition of myostatin signaling has been explored as a strategy to preserve or increase lean mass. In animal models, myostatin blockade has been shown to induce muscle hypertrophy. However, the translation of these findings to human aging populations remains under investigation. The clinical trial of trevogrumab (an anti-myostatin antibody) and garetosmab (an anti-activin A antibody) with semaglutide represents an effort to apply this mechanism in humans with obesity [2].
Anabolic resistance and protein turnover in older adults
Aging is associated with anabolic resistance, a diminished muscle protein synthetic response to amino acids and resistance exercise. This contributes to the gradual loss of lean mass. While the exact molecular mechanisms are complex, they involve alterations in mTOR signaling, satellite cell function, and inflammatory status. Current research focuses on nutritional and pharmacological interventions to overcome anabolic resistance. However, the evidence block does not provide specific studies on this mechanism, so further details are beyond the scope of this article.
Hormonal changes and lean mass in aging
Age-related declines in testosterone, estrogen, and growth hormone/IGF-1 contribute to the loss of lean mass. These hormonal shifts affect muscle protein balance and regenerative capacity. While hormone replacement therapies have been studied, their risk-benefit profile in older adults is debated. The evidence block does not include specific studies on hormonal interventions for lean mass preservation, so this section remains general.
Inflammatory milieu and sarcopenia
Chronic low-grade inflammation, often termed inflammaging, is implicated in the pathogenesis of sarcopenia. Pro-inflammatory cytokines such as TNF-α and IL-6 promote muscle catabolism. Anti-inflammatory strategies are being explored, but no specific compounds are detailed in the evidence block. Therefore, this section is limited to the conceptual framework.
Comparative table of investigational approaches
The table below summarizes key features of the approaches discussed, based on the available evidence.
| Approach | Mechanism | Model | Key Findings |
|---|---|---|---|
| GLP-1 receptor agonists | Incretin mimetic | Human (obesity) | Weight loss, but lean mass loss observed; limitations include plateaus and regain [1] |
| Trevogrumab + garetosmab + semaglutide | Myostatin/activin inhibition + GLP-1 RA | Human (obesity, healthy) | Under investigation for lean mass preservation [2] |
Future directions in lean mass preservation research
Next-generation approaches for obesity treatment are focusing on multi-receptor agonists, oral formulations, and body composition modulation [1]. The goal is to achieve weight loss while preserving lean mass, particularly in aging populations. Clinical trials such as NCT06299098 are evaluating combination therapies that pair GLP-1 receptor agonists with muscle-preserving agents [2]. These studies will provide critical data on the safety and efficacy of such strategies.
If you are reading this for personal health reasons
The compounds mentioned in this article are sold for laboratory research purposes only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies.
- [2] A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation